Indirect comparisons of adverse events and dropout rates in early Parkinson's disease trials of pramipexole, ropinirole, and rasagiline

International Journal of Neuroscience

Volumn 122, Issue 7, 2012, Pages 345-353

  Zagmutt, Francisco J ^a   Tarrants, Marcy L ^b  

^a EpiX Analytics   (United States)

^b Teva Neuroscience   (United States)

Author keywords

bayesian; meta analysis; monotherapy; Parkinson's disease; safety profile

Indexed keywords

PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE;

ADVERSE DRUG REACTION; AMNESIA; ARTICLE; ASTHENIA; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DELUSION; DEPRESSION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; ILLUSION; INCIDENCE; INSOMNIA; MONOTHERAPY; NAUSEA; OUTCOME ASSESSMENT; PARKINSON DISEASE; SIDE EFFECT; SLEEP; SOMNOLENCE; TREATMENT WITHDRAWAL;

ANTIPARKINSON AGENTS; BENZOTHIAZOLES; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; DATABASES, BIBLIOGRAPHIC; FATIGUE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; INDANS; INDOLES; LOGISTIC MODELS; MALE; PARKINSON DISEASE; PATIENT DROPOUTS; SLEEP DISORDERS; TREATMENT OUTCOME;

EID: 84862167051     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2012.660586     Document Type: Article

References (34)

1. Gallagher DA, Schrag A. Impact of newer pharmacological treatments on quality of life in patients with parkinson's disease. CNS Drugs. 2008;22(7):563-86. (Pubitemid 351822118)
2. Jankovic J. Parkinson's disease: Clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368-76. (Pubitemid 351441488)
3. Pahwa R, Lyons KE. Early diagnosis of parkinson's disease: Recommendations from diagnostic clinical guidelines. Am J Manag Care. 2010;16(Suppl Implications):S94-9.
4. Macleod AD, Counsell CE, Ives N, Stowe R. Monoamine oxidase b inhibitors for early parkinson's disease. Cochrane Db Syst Rev. 2005;(3):CD004898.
5. Miyasaki JM,MartinW, Suchowersky O,Weiner WJ, Lang AE. Practice parameter: Initiation of treatment for parkinson's disease: An evidence-based review: Report of the quality standards subcommittee of the american academy of neurology. Neurology. 2002;58(1):11-7. (Pubitemid 34041931)
6. Olanow CW. The role of dopamine agonists in the treatment of early parkinson's disease. Neurology. 2002;58(2):33-41.
7. Lopez IC, Ruiz PJ, Del Pozo SV, Bernardos VS.Motor complications in parkinson's disease: Ten year follow-up study. Mov Disord. 2010;25(16):2735-9.
8. Chen JJ, Swope DM. Pharmacotherapy for parkinson's disease. Pharmacotherapy. 2007;27(12 Part 2):161S-73S. (Pubitemid 350234306)
9. Thobois S. Proposed dose equivalence for rapid switch between dopamine receptor agonists in parkinson's disease: A review of the literature. Clin Ther. 2006;28(1):1-12. (Pubitemid 43254985)
10. Stowe RL, Ives NJ, Clarke C, van Hilten J, Ferreira J, Hawker RJ, Shah L, Wheatley K, Gray R. Dopamine agonist therapy in early parkinson's disease. Cochrane Database Syst Rev. 2008(2):CD006564.
11. Chen JJ, Swope DM, Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of parkinson's disease. Clin Ther. 2007;29(9):1825-49. (Pubitemid 350212811)
12. Chen JJ, Ly A-V. Rasagiline: A second-generation monoamine oxidase type-b inhibitor for the treatment of parkinson's disease. Am J Health Syst Pharm. 2006;63(10):915-28. (Pubitemid 43764968)
13. Parkinson SG. A controlled, randomized, delayed-start study of rasagiline in early parkinson disease. Arch Neurol. 2004;61(4):561-6.
14. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions ver. 5.1.0 [updated march 2011]: The Cochrane Collaboration; 2011. Available from: www.cochranehandbook. org.
15. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in metaanalysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683-91. (Pubitemid 27341818)
16. R development core team. R: A language and environment for statistical computing. R foundation for statistical computing, vienna, austria. 2011. Available from: http://www.R-project.org.
17. Spiegelhalter D, Abrams K, Myles J. Bayesian approaches to clinical trials and health-care evaluation. 1st ed. Chichester: John Wiley & Sons; 2004. Chapter 8, Evidence synthesis; p. 267-99.
18. Lunn DJ, Thomas A, Best N, Spiegelhalter D. Winbugs - a bayesian modelling framework: Concepts, structure, and extensibility. Stat Comput. 2000;10(4):325-37.
19. Parkinson SG. Safety and efficacy of pramipexole in early parkinson disease. A randomized dose-ranging study. Parkinson study group. JAMA. 1997;278(2):125-30.
20. Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: Report of the ispor task force on indirect treatment comparisons good research practices: Part 2. Value Health. 2011;14:429-37.
21. Cooper NJ, Sutton AJ,MorrisD, Ades AE,Welton NJ. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Stat Med. 2009;28(14):1861-81.
22. Kulisevsky J, Pagonabarraga J. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of parkinson's disease: Meta-analysis of randomized controlled trials. Drug Saf. 2010;33(2):147-61.
23. Michinaga S, Hisatsune A, Isohama Y, Katsuki H. An anti-parkinson drug ropinirole depletes orexin from rat hypothalamic slice culture. Neurosci Res. 2010;68(4):315-21.
24. Etminan M, Gill S, Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with parkinson's disease: A meta-analysis. Drug Safety. 2003;26(6):439-44. (Pubitemid 36560715)
25. Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, Taylor RL, Sanchez-Ramos J,O'Brien CF. Ropinirole for the treatment of early parkinson's disease. The ropinirole study group. Neurology. 1997;49(2):393-9. International Journal (Pubitemid 27368872)
26. Shannon KM, Bennett JP, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate parkinson's disease. The pramipexole study group. Neurology. 1997;49(3):724-8. (Pubitemid 27428013)
27. Goetz CG. [movement disorder society-unified parkinson's disease rating scale (mds-updrs): A new scale for the evaluation of parkinson's disease]. Rev Neurol (Paris). 2010;166(1):1-4.
28. Hoehn MM, Yahr MD. Parkinsonism: Onset, progression and mortality. Neurology. 1967;17(5):427-42.
29. Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc. 2009;172(1):137-59.
30. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1(1):43-6. (Pubitemid 20255621)
31. Berry DA, Hochberg Y. Bayesian perspectives on multiple comparisons. J Statist Plann Inference. 1999;82(1):215-27.
32. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: Empirical evidence from published meta-analyses. BMJ. 2003;326(7387):472.
33. Ceravolo R, Frosini D, Rossi C, Bonuccelli U. Impulse control disorders in parkinson's disease: Definition, epidemiology, risk factors, neurobiology andmanagement. Parkinsonism Relat Disord. 2009;15(Suppl 4):S111-5.
34. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in parkinson disease: A cross-sectional study of 3090 patients. Arch Neurol. 2010;67(20457959):589-95.